A&O Shearman Releases Second Life Sciences and Healthcare Insights Report
Summary
A&O Shearman has released the second edition of its Life Sciences and Healthcare Insights report. The publication covers six topics including shareholder activism trends, AI use in drug discovery, China's emergence as a pharma innovation hub, proposed EU MDR and IVDR reforms, the UPC's impact on European patent litigation, and EU environmental sustainability requirements for pharmaceutical companies. The report is informational and does not create compliance obligations.
What changed
A&O Shearman published its second Life Sciences and Healthcare Insights report covering six topics relevant to life sciences and healthcare companies globally. Topics include shareholder activism trends, AI applications in drug discovery with focus on data provenance, China's pharmaceutical market expansion, proposed EU MDR and IVDR framework reforms, the UPC's impact on European patent litigation after two years, and EU environmental sustainability obligations for pharma companies.
Affected parties should review the report for informational purposes only. This is a law firm publication summarizing regulatory trends and does not create new compliance obligations. Healthcare companies, pharmaceutical manufacturers, and investors should monitor the identified trends in shareholder activism, AI governance, and EU regulatory reforms as they develop.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
April 14, 2026
Launching the latest edition of our Life sciences and healthcare insights
Matthew Appleton, Jim Ford, Marjan Noor, Clare O’Brien A&O Shearman + Follow Contact LinkedIn Facebook X Send Embed
We have recently released the second edition of our Life sciences and healthcare insights report, where our global team explore the most important commercial, legal and regulatory issues facing life sciences and healthcare companies around the world.
We open by examining the rise of shareholder activism in life sciences and healthcare, exploring why the sector is under increased scrutiny and how boards can best prepare and respond.
We then explore the growing use of AI in drug discovery and development, focusing on how data provenance is becoming a critical driver of deal value, risk allocation, and regulatory compliance.
Our third article analyses China’s emergence as a global pharmaceutical innovation hub, unpacking the deal structures, regulatory hurdles, IP strategy, and data-transfer issues shaping international expansion.
We assess proposed reforms to the EU’s MDR and IVDR frameworks, explaining how policymakers aim to ease regulatory burden, support innovation, and secure supply —while grappling with AI, cybersecurity, and enhanced post market oversight.
Marking two years of the UPC, we review how it is reshaping European patent litigation and what its expanding case law means for enforcement, risk management, and cross border strategy in life sciences.
Finally, we examine how the EU’s expanding environmental and sustainability agenda is transforming the regulatory and compliance landscape for pharmaceutical companies, often at significant operational and financial cost.
[View source.]
Related Posts
- Life Sciences And Healthcare Insights (UPDATED)
- What Will 2026 Hold For Life Sciences And Biopharma?
- Life Sciences and Healthcare Insights
- Antitrust in Life Sciences—Key European Developments for Pharma Companies
Latest Posts
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.
©
A&O Shearman
Written by:
A&O Shearman Contact + Follow Matthew Appleton + Follow Jim Ford + Follow Marjan Noor + Follow Clare O’Brien + Follow more less
PUBLISH YOUR CONTENT ON JD SUPRA
- ✔ Increased readership
- ✔ Actionable analytics
- ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra
Published In:
Artificial Intelligence + Follow China + Follow Data Management + Follow Environmental Policies + Follow EU + Follow Healthcare + Follow Innovation + Follow Intellectual Property Protection + Follow Life Sciences + Follow Medical Devices + Follow Patent Litigation + Follow Patents + Follow Pharmaceutical Industry + Follow Regulatory Reform + Follow Regulatory Requirements + Follow Risk Management + Follow Shareholders + Follow Sustainability + Follow Health + Follow Intellectual Property + Follow Science, Computers & Technology + Follow more less
A&O Shearman on:
"My best business intelligence, in one easy email…"
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Sign Up Log in ** By using the service, you signify your acceptance of JD Supra's Privacy Policy.* - hide - hide
Related changes
Get daily alerts for JD Supra Healthcare
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from A&O Shearman.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when JD Supra Healthcare publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.